Femasys earnings release, August 14, 2026

Femasys Inc (FEMY) · Form 8-K, Item 2.02 · Filed · SEC filing

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the

FemBloc® clinical and regulatory program toward U.S. approval --

ATLANTA, August 14, 2026 – Femasys Inc.

(NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.

Corporate Highlights from 2Q 2026 to date

“During the second quarter of 2026 and into the third quarter of 2026, we made meaningful progress strengthening our financial position, advancing our commercial strategy and expanding the reach of our innovative fertility solutions,” said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. “The completion of our $30 million private placement and restoration of Nasdaq compliance provide a stronger foundation to execute our growth strategy. We also achieved important commercial milestones, including the launch of FemaSeed Complete at ACOG 2026 and initial commercial use, advancing our strategy to expand access to first-line fertility treatment in the OB/GYN office and potentially enable earlier intervention. With this financing in place, we are well positioned to execute our commercial strategy, complete the U.S. FemBloc clinical program and advance our portfolio toward key value-creating milestones for patients and shareholders.”

Financial Results for Six Months Ended June 30, 2026

Financial Results for Quarter Ended June 30, 2026

For more information, please refer to the Company’s Form 10-Q filed August 14, 2026, which can be accessed on the SEC website.

FEMASYS INC.

Condensed Balance Sheets

(unaudited)

(continued)

FEMASYS INC.

Condensed Balance Sheets

(unaudited)

FEMASYS INC.

Condensed Statements of Operations and Comprehensive Loss

(unaudited)

About Femasys Inc.

Femasys is a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide. The Company is focused on commercializing its fertility portfolio, led by FemaSeed®

Intratubal Insemination, together with complementary diagnostic and sperm preparation products, in the U.S. and key international markets. Femasys is also advancing FemBloc®, its non-surgical, in-office permanent birth control solution, toward U.S. FDA approval through the ongoing FINALE pivotal trial (NCT05977751). FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025, supporting commercialization through strategic partnerships in select international markets. Femasys’ portfolio is supported by broad intellectual property protection and clinical data demonstrating favorable safety, encouraging effectiveness results, and high patient and practitioner satisfaction.

Learn more at www.femasys.com, or follow us on

X,

Facebook and

LinkedIn.

Financial statements

Income Statement

Three Months Ended June 30, — (unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Sales331,827409,268756,716750,532
Cost of sales (excluding depreciation expense)142,436158,171301,042275,437
Operating expenses:Research and development1,946,8781,414,4293,256,2794,382,901
Operating expenses:Sales and marketing1,293,998984,9772,609,7531,893,544
Operating expenses:General and administrative1,931,5781,616,9723,713,9683,339,685
Operating expenses:Depreciation and amortization82,81186,285165,081171,138
Operating expenses:Total operating expenses5,255,2654,102,6639,745,0819,787,268
Operating expenses:Loss from operations-5,065,874-3,851,566-9,289,407-9,312,173
Other income (expense):Interest income19,69417,14469,52136,173
Other income (expense):Change in fair value of conversion option liability219,0001,732,413
Other income (expense):Change in fair value of warrants liabilities545,0004,228,000
Other income (expense):Interest expense-186,050-491,500-362,657-950,949
Other income (expense):Other expense-260,000-260,000
Other income (expense):Total other income (expense), net597,644-734,3565,667,277-1,174,776
Other income (expense):Loss before income taxes-4,468,230-4,585,922-3,622,130-10,486,949
Other income (expense):Income tax expense (benefit)865865-4,188
Other income (expense):Net loss-4,469,095-4,585,922-3,622,995-10,482,761
Other income (expense):Net loss attributable to common stockholders-4,469,095-4,585,922-3,622,995-10,482,761
Other income (expense):Basic and diluted loss per share-1.33-3.18-1.08-7.76
Other income (expense):Weighted-average common shares outstanding, basic and diluted3,357,1171,444,0363,344,7671,351,264

Balance Sheet

June 30, 2026 — (unaudited)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents1,443,5029,266,353
Current assets:Accounts receivable, net151,049616,600
Current assets:Inventory6,191,2775,740,249
Current assets:Prepaid and other current assets546,085833,133
Current assets:Total current assets8,331,91316,456,335
Property and equipment, at cost:Leasehold improvements1,238,8861,238,886
Property and equipment, at cost:Office equipment87,51578,155
Property and equipment, at cost:Furniture and fixtures424,586417,876
Property and equipment, at cost:Machinery and equipment3,121,1313,065,713
Property and equipment, at cost:Construction in progress919,412897,885
Property and equipment, at cost:5,791,5305,698,515
Property and equipment, at cost:Less accumulated depreciation-3,932,324-3,802,940
Property and equipment, at cost:Net property and equipment1,859,2061,895,575
Long-term assets:Lease right-of-use assets, net1,064,3461,297,121
Long-term assets:Intangible assets, net of accumulated amortization115,499134,914
Long-term assets:Other long-term assets918,618940,232
Long-term assets:Total long-term assets2,098,4632,372,267
Long-term assets:Total assets12,289,58220,724,177

Balance Sheet

Liabilities and Stockholders’ Equity — (unaudited)

June 30, 2026December 31, 2025
Current liabilities:Accounts payable2,337,3541,830,124
Current liabilities:Accrued expenses1,033,7121,265,773
Current liabilities:Clinical holdback – current portion42,72652,644
Current liabilities:Operating lease liabilities – current portion473,034487,624
Current liabilities:Total current liabilities3,886,8263,636,165
Long-term liabilities:Clinical holdback – long-term portion54,59852,370
Long-term liabilities:Convertible notes payable, net3,521,2263,178,864
Long-term liabilities:Conversion option liability2,014,000
Long-term liabilities:Warrants liabilities4,943,000
Long-term liabilities:Operating lease liabilities – long-term portion795,9851,030,476
Long-term liabilities:Total long-term liabilities4,371,80911,218,710
Long-term liabilities:Total liabilities8,258,63514,854,875
Stockholders’ equity:Common stock, $0.001 par, 200,000,000 authorized, 3,029,829 shares issued and 3,023,967 outstanding as of June 30, 2026; and 2,986,116 shares issued and 2,980,254 outstanding as of December 31, 20253,0302,986
Stockholders’ equity:Treasury stock, 5,862 common shares-60,000-60,000
Stockholders’ equity:Warrants5,961,1505,246,150
Stockholders’ equity:Additional paid-in capital147,575,906146,506,310
Stockholders’ equity:Accumulated deficit-149,449,139-145,826,144
Stockholders’ equity:Total stockholders’ equity4,030,9475,869,302
Stockholders’ equity:Total liabilities and stockholders' equity12,289,58220,724,177
Full release

Forward-Looking Statements

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the SEC.

Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

# # #

Contacts:

IR@femasys.com

Media@femasys.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.